1 Dec 2014
Enabling genomic medicine
Congenica is a digital health company revolutionising the way diseases are characterised and diagnosed with world leading software enabling rapid interpretation of complex genomic data to provide life-changing answers for patients and their families. Based in Cambridge, UK and born out of pioneering research from the Wellcome Sanger Institute, Congenica has a global footprint and is the exclusive Clinical Decision Support partner for the ground-breaking NHS Genomic Medicine Service
CEO: Rob Denison
CIC oversight: Michael Anstey
Year of investment: 2014
Investment thesis
- The clinical and economic evidence for the use of genomic medicine to characterise disease and diagnose patients is very compelling, reducing diagnostic odysseys to improve health outcomes and generating value for health systems.
- Congenica is able to reduce the working time for interpretation of complex genomic data by >95%, enabling reporting in as little as five minutes, increasing case throughput and diagnostic accuracy to improve outcomes for patients and their families.
“Congenica is delivering a future where clinical genomics is fully integrated into healthcare. Without the support of CIC we would not have been able to accelerate the development of our market leading software for rapid and accurate analysis of complex genomic data to enable rare genetic diagnostics at scale. Their long term vision to support Congenica has helped us establish ourselves in over 20 countries worldwide and provide life-changing answers for patients and their families and generate significant value for healthcare services internationally.”
Andy Richards, Chair of Congenica